BioSpace News Archive

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference.

CytoSorbents Corporation announced that it has received ISO 13485 Certification of its new manufacturing facility in Princeton, New Jersey from its European Union notified body, clearing the way for full manufacturing of CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® from this site, with capacity to add additional product lines as they are developed.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan’s 6th Annual Genetic Medicines Conference.

Novavax, Inc. today announced that an initial one million doses of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine are now available for use in the United Kingdom (U.K.).

Tally Health announced that Melanie Goldey has been appointed Chief Executive Officer and a member of the Board of Directors, effective September 12, 2022.

Viveve Medical, Inc. today announced the launch of a company-wide rebranding initiative that will include content and new graphic elements related to the treatment of SUI in women.

For the first time in three years, the National Comprehensive Cancer Network® (NCCN®) is hosting its yearly blood cancer congress in person.

Stryker (NYSE:SYK), one of the world’s leading medical technology companies, announced today the launch of its Q Guidance System for spine applications.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased to announce the appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the initiation of its Phase 3 global registrational study of zilovertamab, ZILO-301 (NCT05431179), for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL).